Kidney cancer: post-surgery sorafenib
0 Visualizzazioni
• 06/26/23
0
0
Incorporare
administrator
Iscritti
Tim Eisen, MBBChir, PhD, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK, describes the rationale and methodology behind the SORCE trial (NCT00492258) and what have we learned at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti